Cox models vs. machine learning for survival prediction: Do traditional approaches still hold their ground?
Rosalba Miceli(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Toufik Bouhadiba(Institut Curie), Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), Peter C. Ferguson(University of Toronto), Salvatore Provenzano(Fondazione IRCCS Istituto Nazionale dei Tumori), Sylvie Bonvalot(Dana-Farber Cancer Institute), D. Strauß(Royal Marsden Hospital), Gabriele Tinè(Fondazione IRCCS Istituto Nazionale dei Tumori), Anthony M. Griffin(Mount Sinai Hospital), Sandro Pasquali(Fondazione IRCCS Istituto Nazionale dei Tumori), Jay S. Wunder(Sinai Health System), Andrew Hayes(Royal Marsden NHS Foundation Trust), Dimitri Tzanis(Université Paris Cité)
Cited by 0
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
|The Lancet Oncology|2008|2k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k